-
BARRIERS AND FACILITATORS TO PATIENT ENGAGEMENT WITH PATIENT-REPORTED OUTCOME MEASURE COMPLETION IN ROUTINE RADIATION ONCOLOGY CARE
Apr 9, 2026, 18:05 PM -
DERIVATION OF MEANINGFUL WITHIN-PATIENT CHANGE (MWPC) THRESHOLDS OF THE EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER QUALITY OF LIFE QUESTIONNAIRE C30 (EORTC QLQ-C30) PHYSICAL FUNCTIONING (PF) SCORES FROM THE ASCENT-03 TRIAL
Apr 9, 2026, 18:05 PM -
PATIENT PREFERENCES FOR THE TREATMENT OF BCG-UNRESPONSIVE NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC): FINDINGS FROM A UNITED KINGDOM (UK) QUESTIONNAIRE
Apr 9, 2026, 18:05 PM -
EVALUATING AGREEMENT BETWEEN PATIENT-REPORTED CLINICAL TRIAL DATA FROM ADOPT PGX AND MEDICARE AND MEDICAID CLAIMS
Apr 9, 2026, 18:05 PM -
PATIENT-REPORTED OUTCOMES AFTER KIDNEY TRANSPLANTATION: REAL-WORLD EVIDENCE OF BURDEN POST-TRANSPLANT
Apr 9, 2026, 17:58 PM -
HOW SOCIETY VALUES HEALTH: UNEQUAL CONTRIBUTIONS OF PHYSICAL AND MENTAL WELL-BEING TO SOCIAL WELFARE
Apr 9, 2026, 17:58 PM -
AGE AND GENDER-SPECIFIC DIMENSIONALITY OF THE SATISFACTION WITH LIFE SCALE
Apr 9, 2026, 17:58 PM -
COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF THE TRIVALENT ADJUVANTED INFLUENZA VACCINE IN PEOPLE OVER 50 YEARS OF AGE FOR ARGENTINA
Apr 9, 2026, 17:32 PM -
CONSIDERATION OF INDIRECT EFFECTS IN NATIONAL VACCINE EVALUATIONS AND RECOMMENDATIONS: A SCOPING REVIEW
Apr 9, 2026, 17:32 PM -
ECONOMIC EVALUATIONS AND VALUE CONSIDERATIONS IN ACIP ROUTINE VACCINE RECOMMENDATIONS: A COMPREHENSIVE REVIEW
Apr 9, 2026, 17:32 PM -
DEVELOPMENT OF THE MEDICAL DEVICE ECONOMIC EVALUATION METHODOLOGICAL QUALITY (DEEM-Q) CHECKLIST
Mar 19, 2026, 15:43 PM -
POTENTIAL ENVIRONMENTAL AND ECONOMIC IMPLICATIONS OF ROBOTIC ASSISTED SURGERY FOR UROLOGIC ONCOLOGY
Mar 19, 2026, 15:43 PM -
DECISION-RELEVANT EARLY HEALTH ECONOMIC MODELLING TO INFORM DEVELOPMENT AND INVESTMENT IN EMERGING HEALTH TECHNOLOGIES
Mar 19, 2026, 15:43 PM -
BUDGET IMPACT OF ADOPTING A TRI-LAYER HYBRID SURGICAL MESH FOR VENTRAL HERNIA REPAIR: A U.S. HOSPITAL PERSPECTIVE
Mar 19, 2026, 15:43 PM -
COMPARING THE RISK OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE EXACERBATIONS BETWEEN GABAPENTINOIDS AND DULOXETINE
Mar 19, 2026, 15:42 PM -
REAL-WORLD SAFETY PROFILE OF PEMBROLIZUMAB VS. NIVOLUMAB AND CETUXIMAB IN ADULTS WITH HEAD AND NECK SQUAMOUS CELL CARCINOMA: A COMPARATIVE ANALYSIS
Mar 19, 2026, 15:42 PM -
REAL-WORLD HEALTHCARE RESOURCE UTILIZATION AND COSTS OF HOSPITAL-ONSET METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS NON-VENTILATOR-ASSOCIATED PNEUMONIA IN U.S. HOSPITALS: 2023-2025
Mar 19, 2026, 15:42 PM -
REAL-WORLD TREATMENT PATTERNS AND OUTCOMES IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER TREATED WITH RADICAL CYSTECTOMY BY CISPLATIN ELIGIBILITY STATUS: A US MULTICENTER CHART REVIEW STUDY
Mar 19, 2026, 15:42 PM -
BURDENOFHOSPITALACQUIREDPRESSURE INJURIES(HAPIS)AMONGST HIGH-RISK HOSPITALIZED PATIENTS:AREAL-WORLD ANALYSIS
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS OF GLP-1 RECEPTOR AGONISTS VERSUS SGLT2 INHIBITORS FOR CARDIOVASCULAR PROTECTION AMONG U.S. ADULTS WITH DIABETES: A MEPS-BASED ECONOMIC EVALUATION 2022
Mar 18, 2026, 21:38 PM
